104 related articles for article (PubMed ID: 28703285)
1. Cervical mesonephric hyperplasia lacks KRAS/NRAS mutations.
Mirkovic J; Schoolmeester JK; Campbell F; Miron A; Nucci MR; Howitt BE
Histopathology; 2017 Dec; 71(6):1003-1005. PubMed ID: 28703285
[No Abstract] [Full Text] [Related]
2. Atypical Mesonephric Hyperplasia of the Uterus Harbors Pathogenic Mutation of Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (
Kim H; Yoon N; Woo HY; Lee EJ; DO SI; Na K; Kim HS
Cancer Genomics Proteomics; 2020; 17(6):813-826. PubMed ID: 33099482
[TBL] [Abstract][Full Text] [Related]
3. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.
Mirkovic J; Sholl LM; Garcia E; Lindeman N; MacConaill L; Hirsch M; Dal Cin P; Gorman M; Barletta JA; Nucci MR; McCluggage WG; Howitt BE
Mod Pathol; 2015 Nov; 28(11):1504-14. PubMed ID: 26336887
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
6. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
7. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
8. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
[TBL] [Abstract][Full Text] [Related]
9. PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
Rabban JT; McAlhany S; Lerwill MF; Grenert JP; Zaloudek CJ
Am J Surg Pathol; 2010 Feb; 34(2):137-46. PubMed ID: 20061933
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
11. RAS status in Korean patients with stage III and IV colorectal cancer.
Lee WS; Lee JN; Baek JH; Park YH
Clin Transl Oncol; 2015 Sep; 17(9):751-6. PubMed ID: 25997687
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
Kwon MJ; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY
Pathol Res Pract; 2017 Jun; 213(6):654-658. PubMed ID: 28551389
[TBL] [Abstract][Full Text] [Related]
13. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
[TBL] [Abstract][Full Text] [Related]
14. KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
Vendramini E; Bomben R; Pozzo F; Benedetti D; Bittolo T; Rossi FM; Dal Bo M; Rabe KG; Pozzato G; Zaja F; Chiarenza A; Di Raimondo F; Braggio E; Parikh SA; Kay NE; Shanafelt TD; Del Poeta G; Gattei V; Zucchetto A
Leukemia; 2019 Aug; 33(8):2111-2115. PubMed ID: 30872781
[No Abstract] [Full Text] [Related]
15. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
[TBL] [Abstract][Full Text] [Related]
16. Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.
Liang DC; Chen SH; Liu HC; Yang CP; Yeh TC; Jaing TH; Hung IJ; Hou JY; Lin TH; Lin CH; Shih LY
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28853218
[TBL] [Abstract][Full Text] [Related]
17. Mesonephric remnants, hyperplasia, and neoplasia in the uterine cervix. A study of 49 cases.
Ferry JA; Scully RE
Am J Surg Pathol; 1990 Dec; 14(12):1100-11. PubMed ID: 2252101
[TBL] [Abstract][Full Text] [Related]
18. Mesonephric remnants or hyperplasia can cause abnormal pap smears: a study of three cases.
Welsh T; Fu YS; Chan J; Brundage HA; Rutgers JL
Int J Gynecol Pathol; 2003 Apr; 22(2):121-6. PubMed ID: 12649665
[TBL] [Abstract][Full Text] [Related]
19. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
20. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]